General form of registration statement for all companies including face-amount certificate companies

4. Significant Strategic Drug Development Collaborations (Details Narrative)

v3.5.0.2
4. Significant Strategic Drug Development Collaborations (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Jun. 30, 2016
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Shares issued for equity investment, value $ 337,340 $ 10,811,196    
Basis Of Presentation And Significant Accounting Policies [Table] [Default Label]        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Shares issued for equity investment, shares 333,334      
Warrant granted to purchase common stock, common shares available for purchase       353,563
SynBio LLC [Member] | Stock subscription and collaborative development agreement [Member]        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Revenue recognized $ 0      
Percent ownership in Xenetic 39.00% 41.60%    
Warrant granted to purchase common stock, common shares available for purchase   204,394    
Serum Institute of India Ltd [Member] | License and supply agreements [Member]        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Revenue recognized $ 0      
Percent ownership in Xenetic 8.50% 9.20%    
Warrant granted to purchase common stock, common shares available for purchase   96,970    
Baxalta [Member] | Research, development, license and supply agreement [Member]        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Shares issued for equity investment, shares   324,097    
Shares issued for equity investment, value   $ 10,000,000    
Revenue recognized     $ 1,000,000  
Percent ownership in Xenetic 8.00% 8.70%    
Consultant [Member]        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Warrant granted to purchase common stock, common shares available for purchase 25,243      
Non-Employee Director [Member]        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Warrant granted to purchase common stock, common shares available for purchase   48,485